✦ LIBER ✦

806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION

✍ Scribed by Colombo, M.; Fernández, I.; Abdurakhmanov, D.; Ferreira, P.A.; Strasser, S.; Urbanek, P.; Moreno, C.; Streinu-Cercel, A.; Beeldens, F.; Iraqi, W.; DeMasi, R.; Hill, A.; Läuffer, J.M.; Lonjon-Domanec, I.; Wedemeyer, H.

Book ID: 123368429
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 77 KB
Volume: 58
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(13)60808-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Management and outcomes of side effects

Management and outcomes of side effects with focus on anaemia in patients with hepatitis C genotype 1 infection: the telaprevir early access program in patients from Romania

✍ Streinu-Cercel, Adrian; Trifan, Anca Victorița; Căruntu, Florin Alexandru; Spore 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 88 KB

Treatment of hepatitis C genotype 1 pati

Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania

✍ Streinu-Cercel, Adrian; Trifan, Anca Victorița; Căruntu, Florin Alexandru; Spore 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 86 KB

OC-26 Treatment of hepatitis C genotype

OC-26 Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the Italian telaprevir early access program

✍ Colombo, M.; Picciotto, A.; Andreone, P.; Babudieri, S.; Zuin, M.; Mazzella, G.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 58 KB

UK consensus guidelines for the use of t

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

✍ P. Ramachandran; A. Fraser; K. Agarwal; A. Austin; A. Brown; G. R. Foster; R. Fo 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB

Predictive value of the IFNL4 polymorphi

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C

✍ Fujino, Hatsue; Imamura, Michio; Nagaoki, Yuko; Kawakami, Yoshiiku; Abe, Hiromi; 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 398 KB

Clinical utility of the ARCHITECT HCV Ag

Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection

✍ Johannes Vermehren; Simone Susser; Annemarie Berger; Dany Perner; Kai-Henrik Pei 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 300 KB